Non-small cell lung cancer
Conditions
Interventions
Observation group:None
Sponsors
Cancer Hospital Affiliated to Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients must meet all of the following inclusion criteria to be enrolled in this study: 1. Sign the informed consent form and voluntarily join this study; 2. Histological/cellular pathological test confirmed as non-small cell lung cancer; 3. Age>=18 years old; 4. The investigator judges that the patient can receive camrelizumab monotherapy or combination therapy. 5.No prior systemic therapy for advanced/metastatic disease.
Exclusion criteria
Exclusion criteria: Patients with any of the following cannot be enrolled in this study: 1. Patients who have been treated with other immunological drugs or therapies at the same time; 2. Patients who are participating in other interventional studies; 3. Patients with other malignant tumors at the same time; 4. Confirmed pregnancy and lactating females; 5. Any other condition that, in the opinion of the investigator, the patient is not suitable to participate in this study. 6.Patients with cognitive impairment or education level limitations, unable to understand the content of the scale, and unable to cooperate with the quality of life scale.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life; | — |
Countries
China
Contacts
Public ContactWang Haiyong
Cancer Hospital Affiliated to Shandong First Medical University
Outcome results
None listed